优化肌萎缩侧索硬化临床试验的入组标准
该研究评估了ALS临床试验入组标准对排除率、普遍性和结局异质性的影响,并探讨基于风险的选择标准的价值。通过文献检索总结38项试验的入组标准,并将其应用于2904例连续ALS患者,发现排除率高达14%-95%,入组标准仅轻微改善生存和功能下降的异质性,且不优于预测模型。
要点
- ALS试验入组标准导致多数患者被排除,影响结果普遍性。
- 入组标准未显著降低生存时间或功能下降的异质性。
- 基于个体化风险的选择可能平衡试验设计与普遍性损失。
核心结论
- 多数ALS患者因入组标准被排除,试验结果普遍性存疑。
- 入组标准仅轻微改善终点异质性,个体化风险标准或可平衡设计获益与普遍性损失。
研究设计与样本
- 文献检索总结38项临床试验的入组标准,并应用于2904例连续ALS发病队列。
- 使用个体化生存预测模型评估基于风险的选择方法对试验设计的影响。
主要发现
- 38项试验中,除男性比例(p=0.21)外,入组患者的所有特征存在大幅变异(p<0.001)。
- 排除率范围为14%至95%,平均59.8%(95%CI 52.6%-66.7%)。
- 入组标准导致所有预后亚组均有患者被排除。
- 入组标准未降低生存时间异质性(从22.0个月降至20.5个月,p=0.09),也未影响功能下降的个体间变异(从0.62至0.65,p=0.25)。
- 在38项试验中,入组标准在优化样本量和入组率方面均未优于预测模型。
关键数值与推荐
- 排除率范围14%-95%,平均59.8%(95%CI 52.6%-66.7%)。
- 生存时间异质性从22.0个月降至20.5个月(p=0.09)。
- 功能下降个体间变异从0.62至0.65(p=0.25)。
临床怎么用
- 当前入组标准可能过度排除患者,需重新审视其普遍性影响。
- 可考虑采用个体化风险预测模型优化试验入组,平衡设计与普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of eligibility criteria on exclusion rates, generalizability, and outcome heterogeneity in amyotrophic lateral sclerosis (ALS) clinical trials and to assess the value of a risk-based inclusion criterion. METHODS: A literature search was performed to summarize the eligibility criteria of clinical trials. The extracted criteria were applied to an incidence cohort of 2,904 consecutive patients with ALS to quantify their effects on generalizability and outcome heterogeneity. We evaluated the effect of a risk-based selection approach on trial design using a personalized survival prediction model. RESULTS: We identified 38 trials. A large variability exists between trials in all patient characteristics for enrolled patients (p < 0.001), except for the proportion of men (p = 0.21). Exclusion rates varied widely (from 14% to 95%; mean 59.8%; 95% confidence interval 52.6%-66.7%). Stratification of the eligible populations into prognostic subgroups showed that eligibility criteria lead to exclusion of patients in all prognostic groups. Eligibility criteria neither reduce heterogeneity in survival time (from 22.0 to 20.5 months, p = 0.09) nor affect between-patient variability in functional decline (from 0.62 to 0.65, p = 0.25). In none of the 38 trials were the eligibility criteria found to be more efficient than the prediction model in optimizing sample size and eligibility rate. CONCLUSIONS: The majority of patients with ALS are excluded from trial participation, which questions the generalizability of trial results. Eligibility criteria only minimally improve homogeneity in trial endpoints. An individualized risk-based criterion could be used to balance the gains in trial design and loss in generalizability.
引用
- van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019. PMID: 30626653. doi:10.1212/WNL.0000000000006855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。